Proto-Oncogene Proteins c-myc
"Proto-Oncogene Proteins c-myc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
| Descriptor ID |
D016271
|
| MeSH Number(s) |
D12.776.260.103.813 D12.776.624.664.700.189 D12.776.660.765 D12.776.930.125.813
|
| Concept/Terms |
Proto-Oncogene Proteins c-myc- Proto-Oncogene Proteins c-myc
- Proto Oncogene Proteins c myc
- myc Proto-Oncogene Product p62
- myc Proto Oncogene Product p62
- Proto-Oncogene Proteins myc
- Proteins myc, Proto-Oncogene
- Proto Oncogene Proteins myc
- myc, Proto-Oncogene Proteins
- p62 c-myc
- p62 c myc
- p62(c-myc)
- Proto-Oncogene Products c-myc
- Proto Oncogene Products c myc
- c-myc Proteins
- c myc Proteins
- myc Proto-Oncogene Proteins
- Proto-Oncogene Proteins, myc
- myc Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-myc".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-myc".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-myc" by people in this website by year, and whether "Proto-Oncogene Proteins c-myc" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 4 | 5 |
| 2008 | 0 | 4 | 4 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 4 | 7 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 2 | 4 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 4 | 7 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-myc" by people in Profiles.
-
Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains. Nat Biotechnol. 2023 04; 41(4):541-551.
-
Tcf-1 promotes genomic instability and T cell transformation in response to aberrant ?-catenin activation. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201493119.
-
N6 -methyladenosine modification of lncRNA Pvt1 governs epidermal stemness. EMBO J. 2021 04 15; 40(8):e106276.
-
MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chem Biol. 2020 05 21; 27(5):538-550.e7.
-
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
-
Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA. Am J Kidney Dis. 2020 04; 75(4):513-516.
-
Hypusine biosynthesis in ? cells links polyamine metabolism to facultative cellular proliferation to maintain glucose homeostasis. Sci Signal. 2019 12 03; 12(610).
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
-
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018 11 15; 175(5):1244-1258.e26.
-
Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.